Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?

被引：14
|
作者：
Buti, Sebastiano [1 ]
Bersanelli, Melissa [1 ]
机构：
[1] Univ Hosp Parma, Parma, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 16期
关键词：
TRIAL; THERAPY;
D O I：
10.1200/JCO.2016.71.6506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1858 / +
页数：2
相关论文
共 50 条
  • [41] Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
    J S Thompson Coon
    Z Liu
    M Hoyle
    G Rogers
    C Green
    T Moxham
    K Welch
    K Stein
    British Journal of Cancer, 2009, 101 : 238 - 243
  • [42] Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Negrier, S.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] Phase I Study of Sunitinib in Combination With Gemcitabine and Capecitabine for First-Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma
    Bellmunt, Joaquim
    Suarez, Cristina
    Gallardo, Enrique
    Rodon, Jordi
    Pons, Francesc
    Bonfill, Teresa
    Beltran, Marta
    Moya, Irene
    Galtes, Susana
    Albanell, Joan
    Carles, Joan
    ONCOLOGIST, 2014, 19 (09): : 917 - 918
  • [44] Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China
    Lin, Jingyang
    Fang, Qingxia
    Zheng, Xiaochun
    PLOS ONE, 2023, 18 (02):
  • [45] Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
    Zhou, Ai-Ping
    Bai, Yuxian
    Song, Yan
    Luo, Hong
    Ren, Xiu-Bao
    Wang, Xiuwen
    Shi, Benkang
    Fu, Cheng
    Cheng, Ying
    Liu, Jiyan
    Qin, Shukui
    Li, Jun
    Li, Hanzhong
    Bai, Xianzhong
    Ye, Dingwei
    Wang, Jinwan
    Ma, Jianhui
    ONCOLOGIST, 2019, 24 (08): : E702 - E708
  • [46] Sorafenib versus sunitinib as first-line treatment in metastatic renal cell carcinoma: Largest multicenter retrospective analysis.
    Sheng, Xinan
    Zhang, Hailiang
    Li, Xuesong
    Chi, Zhihong
    He, Zhisong
    Ye, Dingwei
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [47] Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
    Coon, J. S. Thompson
    Liu, Z.
    Hoyle, M.
    Rogers, G.
    Green, C.
    Moxham, T.
    Welch, K.
    Stein, K.
    BRITISH JOURNAL OF CANCER, 2009, 101 (02) : 238 - 243
  • [48] Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma
    Miyake, Hideaki
    Matsushita, Yuto
    Watanabe, Hiromitsu
    Tamura, Keita
    Suzuki, Takahisa
    Motoyama, Daisuke
    Ito, Toshiki
    Sugiyama, Takayuki
    Otsukav, Atsushi
    MEDICAL ONCOLOGY, 2018, 35 (10)
  • [49] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON (IFN)-ALFA AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)
    Negrier, S.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2008, 19 : 190 - 190
  • [50] SUNITINIB TREATMENT MODIFICATION IN FIRST-LINE METASTATIC RENAL CELL CARCINOMA: ANALYSIS OF A REAL-WORLD SWEDISH COHORT
    Jakobsson, M.
    Nilsson, F.
    Strambi, A.
    Arpegard, J.
    Dalen, J.
    VALUE IN HEALTH, 2022, 25 (01) : S22 - S22
12345